Birgit Gaschler‐Markefski

Author

Boehringer Ingelheim (Germany)

Also Known As

B Gaschler-Markefski, B. Gaschler-Markefski, Birgit Gaschler-Markefski, Birgit Gaschler‐Markefski

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Leibniz Institute for Neurobiology Otto-von-Guericke University Magdeburg Asklepios Fachkliniken München-Gauting Boehringer Ingelheim (United States)

About

Birgit Gaschler‐Markefski is an author at Boehringer Ingelheim (Germany) specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.4K
2	Health Sciences	7	7	1.2K
3	Social Sciences	3	3	152
4	Language Studies	1	1	20
5	Biostatistics	1	1	64

Birgit Gaschler‐Markefski

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial Martin Reck, R. Kaiser, Anders Mellemgaard, The Lancet Oncology OncologyNintedanib Versus DocetaxelLume-lung 1Metronomic TherapyClinical Trials	2014	931
Lateralized auditory spatial perception and the contralaterality of cortical processing as studied with functional magnetic resonance imaging and magnetoencephalography Marty G. Woldorff, Claus Tempelmann, Juergen Fell, Human Brain Mapping	1999	177
Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors K. Mross, Martin Štefanič, Daniela Gmehling, Clinical Cancer Research	2009	164
Electrodynamic headphones and woofers for application in magnetic resonance imaging scanners Frank Baumgart, Thomas Kaulisch, Claus Tempelmann, Medical Physics	1998	114
The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy: Results from an Open-Label, Randomized Phase II Clinical Trial Martin Sebastian, Martin Reck, Cornelius F. Waller, Journal of Thoracic Oncology Bi 2536Novel Plk-1 InhibitorMedicinePathologyImmune Checkpoint Inhibitor	2010	109
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial Nasser H. Hanna, R. Kaiser, Richard N. Sullivan, Lung Cancer MedicinePharmacologyClinical TrialsPhase Iii TrialImmune Checkpoint Inhibitor	2016	86
Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. Nasser H. Hanna, R. Kaiser, Richard N. Sullivan, Journal of Clinical Oncology Global Phase 3PharmacotherapyPre-clinical PharmacologyOncologyMetronomic Therapy	2013	83
Functional magnetic resonance imaging of a human auditory cortex area involved in foreground–background decomposition Henning Scheich, Frank Baumgart, Birgit Gaschler‐Markefski, European Journal of Neuroscience	1998	82
Auditory stream segregation relying on timbre involves left auditory cortex Susann Deike, Birgit Gaschler‐Markefski, Henning Scheich Neuroreport MusicAuditory ProcessingPsychoacousticsCognitive ScienceAuditory Modeling	2004	80
Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer Silvia Novello, R. Kaiser, Anders Mellemgaard, European Journal of Cancer	2014	65

Page 1